Sol-Gel Technologies Pre-Tax Income 2016-2024 | SLGL
Sol-Gel Technologies pre-tax income from 2016 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Sol-Gel Technologies Annual Pre-Tax Income
(Millions of US $) |
| 2023 |
$-27 |
| 2022 |
$-15 |
| 2021 |
$3 |
| 2020 |
$-29 |
| 2019 |
$-25 |
| 2018 |
$-33 |
| 2017 |
$-32 |
| 2016 |
$-21 |
| 2015 |
$-10 |
Sol-Gel Technologies Quarterly Pre-Tax Income
(Millions of US $) |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$-6 |
| 2023-12-31 |
$-5 |
| 2023-09-30 |
$-6 |
| 2023-06-30 |
$-6 |
| 2023-03-31 |
$-11 |
| 2022-12-31 |
$-6 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-0 |
| 2022-03-31 |
$-6 |
| 2021-12-31 |
$14 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$-8 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-6 |
| 2020-09-30 |
$-9 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$-7 |
| 2019-09-30 |
$-7 |
| 2019-06-30 |
$-5 |
| 2019-03-31 |
$-6 |
| 2018-12-31 |
$-13 |
| 2018-09-30 |
$-8 |
| 2018-06-30 |
$-7 |
| 2018-03-31 |
$-6 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$-6 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.015B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
